saint luke’s cancer institute · 2 saint luke’s cancer institute primary site 2017 oral cavity...
TRANSCRIPT
SAINT LUKE’S CANCER INSTITUTE 2018 ANNUAL REPORT Incorporating the 2017 Cancer Registry Statistical Review
SAI N T LU K E ’ S C A N CER I N S T I T U T E2
Primary Site 2017
Oral Cavity & Pharynx 48
Digestive System 373
Respiratory System 382
Bones & Joints 1
Soft Tissue 8
Skin Excluding Basal & Squamous 57
Breast 561
Female Genital System 78
Male Genital System 177
Urinary System 169
Eye & Orbit 13
Brain & Other Nervous System 75
Endocrine System 66
Lymphoma 110
Myeloma 34
Leukemia 44
Mesothelioma 3
Other 50
All Sites 2,251
20 1 8 A N N UA L R EP O RT 3
Site-specific Conference Interval Number of Conferences
Number of Analytic Cases Presented
Breast Weekly 38 217
Head & Neck Monthly 11 61
Gastrointestinal Weekly 42 301
Gynecologic Bimonthly 21 92
Neuro-oncology Weekly 44 261
Thoracic Weekly 49 280
Totals 205 1,212
SAI N T LU K E ’ S C A N CER I N S T I T U T E4
20 1 8 A N N UA L R EP O RT 5
C AN CE R COM M IT TE E
SAI N T LU K E ’ S C A N CER I N S T I T U T E6
High-Risk Breast Cancer Clinic screening Patients Patients requiring
breast MRI Cancer diagnosed
related to screening
Jan. – Dec. 2016 746 188 4
Jan. – Dec. 2017 1,503 377 8
Jan. – July 2018 506 262 4
20 1 8 A N N UA L R EP O RT 7
SAI N T LU K E ’ S C A N CER I N S T I T U T E8
Lung cancer screening with low-dose CT Patients screened
Patients requiring active surveillance or
follow-up
Patients needing surgical or treatment
intervention
Cancer diagnosed related to screening
Jan. – Dec. 2015 70 6 0 0
Jan. – Dec. 2016 510 69 7 7
Jan. – Dec. 2017 866 138 10 9
Jan. – Sept. 2018 824 149 11 10
20 1 8 A N N UA L R EP O RT 9
SAI N T LU K E ’ S C A N CER I N S T I T U T E10
20 1 8 A N N UA L R EP O RT 11
SAI N T LU K E ’ S C A N CER I N S T I T U T E12
20 1 8 A N N UA L R EP O RT 13
SAI N T LU K E ’ S C A N CER I N S T I T U T E14
Timesrecommended
Timesaccepted Frequency
On-label drug recommended
11 9 81%
O�-label drugrecommended
35 16 45%
Clinical trialrecommended
22
2 (both SLH
clinical trials)
9.5%
20 1 8 A N N UA L R EP O RT 15
SAI N T LU K E ’ S C A N CER I N S T I T U T E16
20 1 8 A N N UA L R EP O RT 17
SAI N T LU K E ’ S C A N CER I N S T I T U T E18
20 1 8 A N N UA L R EP O RT 19
SAI N T LU K E ’ S C A N CER I N S T I T U T E20
20 1 8 A N N UA L R EP O RT 21
SAI N T LU K E ’ S C A N CER I N S T I T U T E22
20 1 8 A N N UA L R EP O RT 23
SAI N T LU K E ’ S C A N CER I N S T I T U T E24
20 1 8 A N N UA L R EP O RT 25
SAI N T LU K E ’ S C A N CER I N S T I T U T E26
20 1 8 A N N UA L R EP O RT 27
470
70
435
435
435
169
29
435
35
35
29291
35
70
291
71
KANSASCITY
KANSASCITY
Independence
Grandview
KANSAS
OverlandPark
Garnett
BlueSprings
Trenton
M I S SOUR I
Missouri River
Kansas River
Lee’sSummit
Smithville
Sta
te L
ine
71
Leavenworth
Liberty
Chillicothe
Butler
Warrensburg
11
N
SAI N T LU K E ’ S C A N CER I N S T I T U T E28
